DEF 14A: Xencor Seeks Stockholder Approval for Equity Incentive Plan Amendment

Xencor is asking stockholders to approve an amendment to its 2023 Equity Incentive Plan to increase the number of authorized shares by 3,000,000.

Summary

• Xencor is seeking stockholder approval to amend and restate its 2023 Equity Incentive Plan to increase the authorized shares by 3,000,000.
• The company believes this increase is necessary to attract, retain, and motivate qualified individuals in the competitive biotechnology industry.
• As of March 31, 2025, 1,734,971 shares were available for issuance under the 2023 Plan, and 15,751,608 shares were subject to outstanding awards.
• The requested additional shares represent approximately 4.2% of the outstanding shares as of March 31, 2025.
• The company's three-year average burn rate was approximately 5.16% for fiscal years 2022 through 2024.
• The annual meeting of stockholders is scheduled for June 12, 2025, where this proposal will be voted on.

Sentiment

Score: 7

Explanation: The document is generally positive, focusing on the need for additional shares to attract and retain talent, and highlighting the company's strong cash position. However, it also acknowledges the competitive landscape and the need to stay on budget.

Positives

• The company believes that increasing the authorized shares will help attract and retain top talent.
• The company ended 2024 with a strong cash position of $706.7 million.
• The company's request is in line with other companies in the biotechnology industry.

Negatives

• The company had to restate its financial statements for the year ended December 31, 2023, and the unaudited financial statements for the quarterly periods ended March 31, 2024, June 30, 2024, and September 30, 2024.

Risks

• Competition for talent in the oncology and autoimmune fields of the biotechnology industry is expected to remain exceptionally strong.
• If the stockholders do not approve the amendment and restatement of the 2023 Plan, the company's ability to recruit and retain top talent will be adversely affected.

Future Outlook

The company believes it can reach meaningful clinical decision points for all its active programs and anticipates initiating a Phase 1b/2a study of plamotamab in patients with rheumatoid arthritis in the first half of 2025, followed by initiations during the second half of the year of a first-in-human study of XmAb657. XmAb942 is expected to enter a Phase 2 study in ulcerative colitis, the most common type of IBD, before the end of 2025.

Management Comments

• We believe that the evolution of our pipeline moves us toward our strengths while minimizing biological uncertainty.
• Xencors future success depends on the ability to attract, retain and motivate highly qualified individuals across our entire organization, as competition for talent in the oncology and autoimmune fields of the biotechnology industry is expected to remain exceptionally strong.

Industry Context

The document highlights the competitive landscape for talent in the biotechnology industry, particularly in the oncology and autoimmune fields, emphasizing the need for competitive equity compensation to attract and retain qualified personnel.

Comparison to Industry Standards

• The document states that the request for additional shares is in line with other companies in the biotechnology industry.
• The company benchmarks its compensation practices against a peer group of 18 biotechnology companies, including Agenus, IGM Biosciences, and Arcus Biosciences, among others.
• The company strives to achieve a burn rate and overhang at approximately the average rates of its peer group.

Stakeholder Impact

• Approval of the equity incentive plan amendment is intended to benefit shareholders by enabling the company to attract and retain talent, which is expected to drive long-term value.
• Employees are impacted by the potential for equity awards, which serve as a motivator and retention tool.

Next Steps

• Stockholders will vote on the proposed amendment and restatement of the 2023 Equity Incentive Plan at the annual meeting on June 12, 2025.

Key Dates

Keywords

equity incentive plan, stockholders, shares, compensation, biotechnology, Xencor